International Agency for Research on Cancer. Population fact sheets[EB/OL]. (2019-05)[2020-05-21]. https://gco. iarc.fr/.
顾秀瑛, 郑荣寿, 张思维, 等. 2000—2014年中国肿瘤登记地 区前列腺癌发病趋势及年龄变化分析[J]. 中华预防医学 杂志, 2018, 52(6): 586-592.
GU X Y, ZHENG R S, ZHANG S W, et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014[J]. Chin J Prev Med, 2018, 52(6): 586-592.
顾成元, 秦晓健, 黄永墙, 等. 我国部分省市前列腺癌精准筛 查初步结果分析[J]. 中华医学杂志, 2019, 99(42): 3292-3297.
GU C Y, QIN X J, HUANG Y Q, et al. The prostate cancer precision screening program: a preliminary report after recruitment of 2 159 men[J]. Nat Med J China, 2019, 99(42): 3292-3297.
杨小奇, 叶章群. 浅谈前列腺特异性抗原的前世今生[J]. 现代泌尿生殖肿瘤杂志, 2019, 11(1): 1-5.
YANG X Q, YE Z Q. The past and present life of prostate-specific antigen[J]. J Contemp Urol Reprod Oncol,2019,11(1): 1-5.
叶定伟, 朱 耀. 中国前列腺癌的流行病学概述和启示 [J]. 中华外科杂志, 2015, 53(4): 249-252.
YE D W, ZHU Y. Epidemiology of prostate cancer in China: an overview and clinical implication[J]. Chin J Surg, 2015, 53(4): 249-252.
陈 涛, 张换友, 詹晓凤, 等. 前列腺特异性抗原在前列腺癌 早期筛查方面的研究[J]. 肿瘤基础与临床, 2016, 29(5): 454-455, 456.
CHEN T, ZHANG H Y, ZHAN X F, et al. Prostate-specific antigen in early screening of prostate cancer[J]. J Basic Clin Oncol, 2016, 29(5): 454-455, 456.
中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌 学组. 前列腺癌筛查专家共识[J]. 中华外科杂志, 2017, 55(5): 340-342.
Prostate Cancer Working Group of Genitourinary Can. Consensus of prostate cancer screening[J]. Chin J Surg, 2017, 55(5): 340-342.
王 一, 刘晓强, 郭战军, 等. PSA及F/T对中国人群前列腺癌 早期诊断的系统评价[J]. 现代泌尿生殖肿瘤杂志, 2009, 1(5): 263-267.
WANG Y, LIU X Q, GUO Z J, et al. PSA and F/T test for early detection of the prostate cancer in Chinese:a systematic review and Meta-analysis[J]. J Contemp Urol Reprod Oncol, 2009, 1(5): 263-267.
刘 雷, 于颖彦. Meta分析方法及其在肿瘤研究中的应用 [J]. 外科理论与实践, 2011, 16(3): 310-313.
LIU L, YU Y Y. Meta-analysis and its application in cancer research[J]. Surg Theory Pract, 2011, 16(3): 310-313.
PENNY W, ANNE W S, JOHANNES B R, et al. QUADAS的制 定:用于系统评价中评价诊断性研究质量的工具[J]. 中 国循证医学杂志, 2007, 7(4): 296-306.
PENNY W, ANNE W S, JOHANNES B R, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews [J]. Chin J Evidence Based Med, 2007, 7(4): 296-306.
卢建明, 米成嵘, 王 文. 前列腺特异性抗原在前列腺癌筛 查中的作用[J]. 宁夏医学杂志, 2011, 33(3): 269-270.
LU J M, MI C R, WANG W. The role of prostate-specific antigen in prostate cancer screening[J]. Ningxia Med J, 2011, 33(3): 269-270.
江先汉, 黄 海, 何慧婵, 等. 前列腺特异性抗原在前列腺癌 中的诊断价值[J]. 肿瘤学杂志, 2011, 17(3): 237-238.
JIANG X H, HUANG H, HE H C, et al. Diagnostic value of prostate-specific antigen in prostate cancer[J]. J Oncol, 2011, 17(3): 237-238.
韩晋峰, 王伟华, 贾 倩. 前列腺特异性抗原、直肠指诊、 经直肠超声在前列腺癌筛查中的价值[J]. 中华实用诊断 与治疗杂志, 2009, 23(5): 476-477.
HAN J F, WANG W H, JIA Q. The value of prostate-specific antigen, digital rectal examination and transrectal ultrasound in prostate cancer screening[J]. J Chin Pract Diag Ther, 2009, 23(5): 476-477.
杨宗珂, 王德林, 杨 研, 等. 前列腺特异性抗原及其相关指 标在前列腺癌鉴别诊断中的应用价值[J]. 中国医学装备, 2015, 12(12): 31-34, 35.
YANG Z K, WANG D L, YANG Y, et al. Research on clinical application value of prostate-specific antigen indexes in the differential diagnosis of benign prostatic hyperplasia and prostate cancer[J]. China Med Equip, 2015, 12(12): 31-34, 35.
朱玉琨, 张 悦, 杨光辉, 等. 血清T-PSA、F-PSA及比值变 化对前列腺疾病的应用分析[J]. 实用医学杂志, 2003, 19(8): 866-867.
ZHU Y K, ZHANG Y, YANG G H, et al. Application analysis of serum T-PSA, F-PSA and ratio changes in prostate diseases [J]. J Pract Med, 2003, 19(8): 866-867.
黄 翔, 潘慈康, 符本琪, 等. 前列腺特异性抗原及其相关 因子在前列腺癌诊断中的应用[J]. 西部医学, 2003, 1(1): 13-15.
HUANG X, PAN C K, FU B Q, et al. Role of PSA、PSAD and fPSA/PSA in diagnosis of prostatic cancer[J]. Med J West China, 2003, 1(1): 13-15.
官琳妹, 李士军. 测定F-PSA/T-PSA对鉴别前列腺癌与前列 腺增生的意义[J]. 大连医科大学学报, 2005, 27(1): 54-56.
GUAN L M, LI S J. Evaluation of measuring F-PSA/T-PSA to distinguish BPH from PCa[J]. J Dalian Med Univ, 2005, 27(1): 54-56.
陈国军, 陆建红, 杨 勇, 等. 血清T-PSA、F/T诊断前列 腺肿瘤及其阳性预警值研究[J]. 武警医学, 2005, 16(3): 174-176.
CHEN G J, LU J H, YANG Y, et al. Serum T-PSA, F/T ratio in diagnosis of prostatic cancer and its positive alarm value[J]. Med J Chin People’s Armed Police Forces, 2005, 16(3): 174176.
高中伟, 刘 刚, 盛彬武. 前列腺癌与前列腺增生患者血清 游离PSA和总PSA的改变[J]. 癌症, 2004, 23(6): 701-703.
GAO Z W, LIU G, SHENG B W. Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia[J]. Chin J Cancer, 2004, 23(6): 701703.
宋佳卉, 孙 萍. 前列腺特异性抗原在老年前列腺疾病中的 诊断价值[J]. 宁夏医科大学学报, 2019, 41(9): 954-956.
SONG J H, SUN P. Diagnostic value of prostate-specific antigen in elderly patients with prostate diseases[J]. J Ningxia Med Univ, 2019, 41(9): 954-956.
SCIARRA A, MAGGI M, FASULO A, et al. Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation[J]. Urologia, 2017, 84(3): 158-164.
王 跃, 戴 波. 中国抗癌协会2017版《前列腺癌筛查专家 共识》解读[J]. 临床外科杂志, 2018, 26(1): 15-18.
WANG Y, DAI B. Interpretation of prostate cancer screening expert consensus of China Anti Cancer Association (2017)[J]. J Clin Surg, 2018, 26(1): 15-18.
SCHRODER F H, HUGOSSON J, ROOBOL M J, et al. Prostatecancer mortality at 11 years of follow-up[J]. N Engl J Med, 2012, 366(11): 981-990.
HUGOSSON J, CARLSSON S, AUS G, et al. Mortality results from the goteborg randomised population-based prostate-cancer screening trial[J]. Lancet Oncol, 2010, 11(8): 725-732.
FRITZ H S, HUGSSON J, ROOBOL M J, et al. Screening and prostate-cancer mortality in a randomized European study[J]. N Engl J Med, 2009, 360(13): 1320-1328.
NADLER R B, HUMPHREY P A, SMITH D S, et al. Effect of inflammation and benign prostatic hyperplasis on elevated serum prostate-specific antigen levels[J]. J Urol, 1995, 154(2 Pt 1): 407-413.
SMITH R A, ANDREWS K S, BROOKS D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening[J]. CA Cancer J Clin, 2019, 69(3): 184210.
EAPEN R S, HERLEMANN A, WASHINGTON S L, et al. Impact of the United States Preventive Services Task Force ‘D’ recommendation on prostate cancer screening and staging[J]. Curr Opin Urol, 2017, 27(3): 205‐209.
陈 松, 杨如武, 郭佑民, 等. CT和MR血管成像诊断急性 肺栓塞的Meta分析[J]. 放射学实践, 2014, 29(12): 14091414.
CHEN S, YANG R W, GUO Y M. Diagnostic ralue of CT angiography and MR angiography for acute pulmonary embolism based on Meta-analysis[J]. Radiol Pract, 2014, 29(12): 1409-1414.
JAIN S, BHOJWANI A G, MELLON J K. Improving the utility of prostate-specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers[J]. Postgrad Med J, 2002, 78(925): 646-650.
LUGHEZZANI G, LAZZERI M, HAESE A, et al. Multicenter European external validation of a prostate health indexbased nomogram for predicting prostate cancer at extended biopsy [J]. Eur Urol, 2014, 66(5): 906-912.
OESTERLING J E, JACOBSEN S J, CHUTE C G, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age specific reference ranges [J]. JAMA, 1993, 270(7): 860-864.
ROEHRBORN C G, MCONNEL J D, LIEBER M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia[J]. Urology, 1999, 53(3): 473480.
PAREKH N, LIN Y, MARCELLA S. Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004)[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(9): 2467-2472.
PIENTA K J. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later[J]. Urology, 2009, 72(5): S11-S20.
朱 刚, 张 凯. 中国前列腺癌筛查的现状和挑战[J]. 山 东大学学报(医学版), 2019, 57(1): 11-15.
ZHU G, ZHANG K. Chinese prostate cancer screening: current situation and challenges[J]. J Shandong Univ (Health Sci), 2019, 57(1): 11-15.